Skip to main content
. 2022 Aug 4;19(15):9616. doi: 10.3390/ijerph19159616

Figure 3.

Figure 3

Meta-analysis bradycardia—RCT. Beta-blocker vs. methyldopa: [27,33,38]; beta-blocker vs. placebo: [45,51,53]; beta-blocker vs. hydralazine: [40,47,59]; beta-blocker vs. calcium channel blocker [33]; beta-blocker with hydralazine vs. placebo: [50].